Biotech | March 29, 2022
USFDA clears IND application for an intranasal RSV vaccine
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
The collaboration leverages Insilico's end-to-end AI-driven Pharma.AI platform to discover novel small molecule drug candidates for multiple targets, along with EQRx's innovative business model to accelerate drug development and patient access to novel medicines at affordable prices
Data to establish the safety profile and human dose of vaccine candidate
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
Intranasal immunization lowers the viral load below the limit of detection in lungs of hamsters
Covaxin is not approved in the USA for any age group
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
Resolv ER may remedy leading causes of blindness in adults
Subscribe To Our Newsletter & Stay Updated
